NAD+: Research Evidence & Trials
This guide collects everything we’ve researched on NAD+ in the area of research evidence & trials. Each question below contrasts what AI assistants report with what the peer-reviewed literature in our research corpus actually shows.
Questions in this guide
- What is the current state of clinical evidence supporting NAD+ supplementation for age-related decline, and how do randomized controlled trials compare to preclinical models in demonstrating efficacy?
- How do meta-analyses of human trials assess the consistency of NAD+ precursor supplementation in improving biomarkers of aging, such as telomere length and epigenetic clocks?
- What are the limitations of current animal studies on NAD+ and how do they affect the translation of findings to human applications?
- What is the current status of NAD+ supplementation in clinical trials for treating age-related macular degeneration or diabetic retinopathy?
Continue your journey
What is the current regulatory and legal status of Epithalon in major jurisdictions (e.g., USA, EU, Canada) for research, personal use, and commercial distribution?Are there any known drug interactions between NAD+ precursors and medications such as statins, anticoagulants, or chemotherapy agents?How does NAD+ depletion during aging affect mitochondrial biogenesis via PGC-1α and SIRT1 signaling, and what is the reversibility of this process with supplementation?How does combining NAD+ precursors with other longevity-promoting compounds (e.g., resveratrol, metformin) affect efficacy and safety profiles?How does NAD+ regulate autophagy through SIRT1 and mTOR signaling, and what role does this play in preventing protein aggregation in neurodegenerative diseases?HMG (human menopausal gonadotropin): Mechanism, Benefits & Research Evidence